Nolvadex / Tamoxifen Citrate: Overview

Modified on 2009/10/14 21:51 by admin
Tamoxifen Citrate, sold under the brand name Nolvadex, is a drug commonly used in conjunction with radiation to treat breast cancer. Nolvadex blocks some of the effects that the hormone estrogen has on the body. The Food & Drug Administration approved it for treatment of breast cancer in 1994. In October 1998, it was approved for use in women at high risk of developing breast cancer. In a recent study published in July 2001, researchers at the Fred Hutchinson Cancer Center discovered that Nolvadex may encourage the growth of treatment resistant tumors. The researchers admit however that their findings are not conclusive.

Nolvadex can have potentially serious side effects including increased risk of endometrial cancer and uterine cancer, deep vein thrombosis (blood clotting in the deep veins), and pulmonary embolism (sudden blocking of an artery in the lung). It can also increase the risk of having a stroke.

In June 2002, the FDA and AstraZeneca Pharmaceuticals LP added a boxed warning and strengthened the WARNINGS section of the label for Nolvadex. Serious, life-threatening or fatal events associated with Nolvadex in the risk reduction setting include endometrial cancer, uterine sarcoma, stroke, and pulmonary embolism. The warning recommends that healthcare providers discuss the potential benefits versus the potential risks of these serious events with women considering Nolvadex to reduce their risk of developing breast cancer. See your doctor if you have experienced serious side effects associated with Nolvadex. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Cancer Drugs: Overview
  2. Blood Clots
  3. Cancer
  4. Deep Vein Thrombosis
  5. Pulmonary Embolism: Overview
  6. Stroke
  Name Size